Table of Contents

Many patients who rely on Eliquis worry about the rising cost of long-term anticoagulation, especially when treatment is indefinite. A 2022 US national survey found that 20.2% of adults skipped or stretched their medications because of cost.

However, missing doses of Eliquis is especially dangerous. A large Danish study of more than 8,000 adults with atrial fibrillation found that people who discontinued their medication were twice as likely to have another stroke compared with those who continued taking it.

With generic apixaban now available in countries like Canada and already approved by the FDA, many patients want to know whether it performs the same as Eliquis and whether switching is safe.

Key Takeaways

  • Strict global regulatory standards ensure generic apixaban matches Eliquis in active ingredient, strength, dosing, and therapeutic use.
  • Bioequivalence testing shows generics reach nearly identical absorption and peak blood levels compared with Eliquis.
  • Real-world patient data confirms that approved generics achieve expected anti-factor Xa levels, indicating reliable anticoagulation.
  • Differences in color, size, or inactive ingredients do not change how apixaban prevents clots.

Regulatory Standards for Generic Drugs

Pink oval pills medicine pharmaceutical drugs laying on a prescription RX pad

A generic medicine is not just a cheaper tablet with the same name. To be approved by regulators such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, or national agencies in other countries, a generic version has to meet strict requirements, including:

    • Same active ingredient
    • Same strength
    • Same dosage form (for example, film-coated tablet)
    • Same route of administration (oral)
    • Same general indication and dosing schedule

Most importantly, the manufacturer has to prove that the generic product is bioequivalent to the reference product, which in this case is Eliquis. Bioequivalence means a generic medicine works in the body the same way and at the same speed as the brand-name drug.

If these conditions are met, the FDA expects the generic to work the same and be just as safe as the brand.

How do they test generic apixaban?

When testing, scientists compare it to the brand drug by measuring:

    • Cmax = the highest level of the drug in your blood
    • AUC = how much total drug your body absorbs over time

For the generic to be accepted, these measurements must be very close to the brand.

The current FDA standard states that the generic’s AUC and Cmax must fall within 80% to 125% of the brand’s values.

To measure this, the FDA first adjusts the numbers to make the comparison between the generic and the brand fair, because drug levels naturally rise and fall due to normal human differences.

After adjusting the numbers, they look at the ratio of generic to brand and calculate a range of values they feel 90% confident about. If that whole range is inside the allowed limits (80-125%), the generic is considered the same as the brand in how it works in the body.

Is Generic Apixaban as Good as Eliquis?

Yes. Several published studies have evaluated generic apixaban formulations.

Bioequivalence studies

Bioequivalence studies are the standard way to show that a generic drug works in the body almost the same as the brand-name drug it is compared to.

In one study, 24 healthy adults (men and women) participated. Each person took one dose of either the generic version (manufactured by Zist Arvand Pharmed, Iran) or the branded version (Eliquis). After a two-week break, they switched and took the other product. This design helps ensure the results are fair and not influenced by individual differences.

Blood samples were collected for 48 hours after each dose to measure how much apixaban entered the bloodstream over time.

Results showed that both drugs, the generic and Eliquis, produced very similar blood levels. Their average Cmax and AUC values were almost the same.

Most importantly, the FDA requires the comparison to fall within 80% to 125%, and all the results from this study were comfortably inside that range:

AUC (total drug absorbed)

91.4% to 105.9%
AUC (total exposure including estimated portion)

92.9% to 106.9%
Cmax

87.1% to 101.9%

A separate study tested whether the generic apixaban 5 mg tablet, manufactured by Sandoz, Canada, works the same way as Eliquis 5 mg. They included 30 healthy men and women, and each person took both the Sandoz apixaban tablet and Eliquis at different times, with breaks in between (a standard “crossover” design).

Blood samples were collected to see how quickly and how much apixaban entered the bloodstream. For all the main measurements, the Sandoz apixaban and Eliquis were almost identical and well within the allowed range:

AUC (total drug absorbed)

94.5% to 101.4%
AUC (total exposure including estimated portion)

94.3% to 101.6%
Cmax

92.1% to 105.6%

Both drugs also peaked at about 2.3 hours after dosing and stayed in the body for a similar length of time, with about half of the drug removed after roughly 8.5 hours.

Based on these results, these generics meet the regulatory standards for bioequivalence and can be expected to work the same way as branded Eliquis.

Efficacy studies

Beyond bioequivalence studies, some researchers have examined real-world drug levels using anti-factor Xa assays, which indicate how well the drug is thinning the blood.

In the study, they included 26 adults (5 men, 21 women), and most were being treated for venous thromboembolism (VTE), and a few for atrial fibrillation (AF). Patients were switched from warfarin or rivaroxaban to generic apixaban (manufactured by Zydus Lifesciences Limited, India) 5 mg twice daily for one month.

About 3-4 hours after the morning dose, blood samples were taken to measure peak anti-Xa levels using two separate accredited laboratories. This test shows whether the drug reaches the expected blood-thinning effect. The expected reference range for apixaban peak levels was 69-321 ng/mL.

The study found:

    • 96.2% of the blood levels were within the expected range.
    • Both labs measured almost identical average values (around 190 ng/mL).
    • The small difference between the two labs’ measurements showed that the results were consistent and reliable.

Overall, the generic apixaban produced blood-thinning levels that match what is normally seen with Eliquis. The results were consistent across two accredited labs. This suggests the generic is effective for patients who need apixaban for VTE or AF.

Differences Between Eliquis and Generic Apixaban

Even when the active ingredient and exposure are similar, there can be practical differences that might matter to you as a patient.

1. Inactive ingredients and tablet appearance

Generic tablets can contain different inactive ingredients, such as fillers, binders, and colorants. These do not affect anticoagulant activity but can change tablet size, shape, or color. For most people, these differences do not matter. For a small number of patients with true allergies or intolerances to certain excipients, the details can be important.

Prescribing information and public assessment reports often list these excipients. For example, the product information for apixaban tablets from various manufacturers describes lactose, cellulose, and other ingredients that help structure the tablet.

If you have known sensitivities to dyes or fillers, you can ask your pharmacist to review the inactive ingredient list of a specific generic brand and discuss alternatives if needed.

2. Tablet scoring and handling

Some patients ask whether they can split apixaban tablets. Most apixaban products, branded or generic, are not designed to be split. Product information usually recommends using the full tablet and not manipulating it unless the label clearly allows splitting.

If a generic tablet is physically smaller or larger than Eliquis, this can influence ease of swallowing, especially for older adults or those with dysphagia. Research groups are exploring alternative formulations such as orally disintegrating films to help certain patient groups take apixaban more easily.

3. Cost and adherence

One reason generics exist is to reduce cost. Eliquis is expensive in many health systems, and cost has been a barrier to wider use of direct oral anticoagulants.

When generic versions bring prices down, patients are more likely to afford continuous therapy, which may improve real-world protection from stroke or recurrent clots. A high-quality generic that a patient can actually afford may lead to better outcomes than a brand product that the same patient cannot take consistently due to cost.

How to Switch from Eliquis to Generic Apixaban Safely

Switching from Eliquis to an approved generic apixaban is usually straightforward since the dose and schedule are the same. Even so, anticoagulants require careful handling because missed doses or sudden changes can affect clotting and bleeding risks.

The steps below describe common clinical guidance. Always follow the instructions given by your own prescriber, as individual situations vary.

  • Continue the same dose and timing

    Most patients simply replace their next scheduled dose of Eliquis with the same strength of generic apixaban. There is no need for tapering, bridging, or overlap because both products contain apixaban and produce similar blood levels when approved by a strict regulator.

  • Do not skip any doses during the transition

    Apixaban protects you from clots only if taken consistently. Missing doses during the switch can reduce anticoagulation. Clinicians usually remind patients to keep the twice-daily schedule steady while replacing one product with the other.

  • Check the tablet strength and appearance before taking the first dose

    Generic tablets may look different in shape or color. Confirm that the label matches the prescribed strength, such as 2.5 mg or 5 mg. Many pharmacies place a sticker on the bottle to help patients distinguish the new tablet from the previous one.

  • Review other medicines and supplements

    Any switch in anticoagulant products is a good time to check for drug interactions. Medicines such as certain antifungals, antiepileptics, antiretrovirals, and some herbal products can change apixaban levels. Your prescriber or pharmacist can help confirm that nothing else in your regimen affects the transition.

  • Monitor for signs of bleeding or clotting

    The risk profile should remain similar when moving from Eliquis to a bioequivalent generic. Even so, you should watch for:
      • unusual bruising
      • nosebleeds that take longer than usual to stop
      • blood in urine or stool
      • swelling or pain in a leg
      • sudden shortness of breath
    Report any of these signs promptly so your healthcare team can evaluate them.

  • Be consistent with one manufacturer when possible

    Although all approved generics must be bioequivalent, some clinicians prefer patients to stay with one specific manufacturer to avoid confusion about pill appearance. If your pharmacy needs to switch to another manufacturer, they can tell you in advance so you can confirm the new tablet strength.

  • Discuss kidney function, age, and body weight with your clinician

    Dose adjustments for apixaban are sometimes recommended in people with reduced kidney function or in those who meet certain age and weight thresholds. These rules apply to both Eliquis and generic apixaban. Your prescriber may review your most recent labs or health history before completing the switch.

  • Verify that the generic is approved by a strict regulator

    Not all global markets have the same quality systems. A generic apixaban approved by the FDA, EMA, Health Canada, the UK MHRA, the Australian TGA, or equivalent agencies has demonstrated bioequivalence. Using a product verified by one of these agencies supports a safe transition.

How to Get High-Quality Generic Apixaban in the US

In the US, the generic version of Eliquis may not be available until at least April 2028 due to patent protections, even though the FDA already approved it in 2019.

However, generic apixaban has been available in Canada since 2022. It contains the same active ingredient, works the same way, and is approved by Health Canada for the same indications, including stroke prevention in atrial fibrillation and treatment of DVT and PE.

Here’s how much you can save on either branded Eliquis or generic apixaban from Canada:

Eliquis

Dose

 Qty US Price* Pharma Giant Price**

Potential Savings

2.5 mg

60 tabs

 $606 $157 $449

120 tabs

 $1,212 $308

$904

180 tabs

 $1,818 $432

$1,386

5 mg

60 tabs

 $606 $157

$449

120 tabs

 $1,212 $308

$904
180 tabs $1,818 $432

$1,386

Generic Apixaban (JAMP Apixaban, manufactured by JAMP Pharma Corporation)

Dose

 Qty US Price* Pharma Giant Price**

Potential Savings

2.5 mg

60 tabs

Not available in the US

Savings are calculated using the branded Eliquis cost

$89

$517

120 tabs

$170

$1,042

180 tabs

$249

$1,569

5 mg

60 tabs

$89

$517

120 tabs

$170

$1,042

180 tabs

$249

$1,569

*Based on the US list price of $606

**Pharma Giant works only with licensed, verified Canadian pharmacies that dispense authentic medications. Every prescription undergoes pharmacist review before approval. All shipments include full tracking and secure packaging.

Is JAMP apixaban as good as Eliquis?

Yes. In its bioequivalence study, JAMP apixaban produced nearly the same blood levels as Eliquis across all major measurements. Because all results were well within the accepted bioequivalence range (80-125%), JAMP Apixaban is expected to work the same way in the body as Eliquis.

The results were as follows:

AUC (total drug absorbed)

91.0% to 101.1%
AUC (total exposure including estimated portion)

93.1% to 102.6%
Cmax

90.9% to 99.6%

How to purchase generic apixaban from Canada?

Here’s how it works:

  • Step 1: Create or access your account

    Register for a Pharma Giant account or log in if you already have one.

  • Step 2: Search for Eliquis or apixaban

    Use the search bar (magnifying glass icon) at the top of the homepage and type in “Eliquis” or “apixaban.” Select the dosage your doctor prescribed, such as 2.5 mg or 5 mg, and click “Buy” to add it to your cart.

  • Step 3: Proceed to checkout

    Once you’re ready, head over to your cart and select “Continue to Checkout.” You’ll be prompted to enter your contact information, shipping address, and payment method. After reviewing everything, hit “Submit.” You’ll receive a confirmation email with your order details.

  • Step 4: Upload your prescription

    Before your medication can be dispensed, Pharma Giant needs a valid prescription from your healthcare provider. You can send it in three different ways:
      • Upload it directly using the RX uploader tool after checkout
      • Email a clear scan or photo to info@pharmagiant.com
      • Fax it to 1-888-562-8159
    If your prescription isn’t received right away, the support team will reach out to help you complete your order without delay.

  • Step 5: Track your shipment

    You will receive a tracking number once your order ships through Canada Post. Most US customers receive their order within 4 to 10 business days. Eliquis does not require cold-chain storage, so it ships safely year-round. Every order is packaged to protect the medication from heat, moisture, and impact during delivery.

Bottom Line

Generic apixaban meets the same strict standards as Eliquis and has been shown in multiple studies to match its absorption, peak levels, and blood-thinning effect. Research confirms that approved generics fall within FDA bioequivalence limits and achieve expected anti-factor Xa levels in real patients.

Differences in tablet appearance do not affect how the drug works, and switching is usually straightforward when doses remain consistent. With strong regulatory oversight and lower cost, high-quality generics offer a safe and effective alternative to Eliquis, especially for patients seeking affordable long-term anticoagulation.

apixaban coupons and discounts

Starts from $89

Ready to Buy Apixaban Online?

Choose Pharma Giant for affordable medications and take control of your health with reliable, cost-effective options today!

SAVE 10% with coupon code:

Frequently Asked Questions

Yes. Apixaban is available in the US, but only the brand-name version, Eliquis, is currently sold in pharmacies. Generic apixaban exists on paper with FDA approval, yet it is not available for US sale because of active patent protections

Generic apixaban has FDA approval, but widespread US availability is delayed until at least 2028 due to patent protections and settlement agreements.

Apixaban is commonly known by its brand name Eliquis.

Some people switch to other anticoagulants like warfarin, Xarelto (rivaroxaban), or Pradaxa (dabigatran), though each has different monitoring needs, dosing schedules, and risk profiles. Cost varies by insurance coverage, pharmacy pricing, and assistance programs.

Some insured patients may qualify for the Eliquis $10 Co-pay Card, which can reduce monthly costs if the prescription meets program criteria. Eligibility usually excludes people on government insurance plans like Medicare or Medicaid.

Eliquis is costly because it is still protected by patents in the US, which prevents generic competition. Research, development, marketing, and insurance pricing negotiations also influence its retail cost.

Prices vary by pharmacy and insurance, but Xarelto is often similarly priced and not consistently cheaper. Some patients may find one more affordable depending on coverage or available discount programs.

Related Articles

Sources

Dusetzina, S. B., Besaw, R. J., Whitmore, C. C., Mattingly, T. J., 2nd, Sinaiko, A. D., Keating, N. L., & Everson, J. (2023). Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022. JAMA network open, 6(5), e2314211. https://doi.org/10.1001/jamanetworkopen.2023.14211

Hindsholm, M. F., Rodríguez, L. a. G., Brandes, A., Hallas, J., Høyer, B. B., Möller, S., Gurol, M. E., Simonsen, C. Z., & Gaist, D. (2024). Recurrent ischemic stroke in patients with atrial fibrillation while receiving oral anticoagulants. JAMA Neurology, 81(8), 805. https://doi.org/10.1001/jamaneurol.2024.1892

Chow S. C. (2014). Bioavailability and Bioequivalence in Drug Development. Wiley interdisciplinary reviews. Computational statistics, 6(4), 304–312. https://doi.org/10.1002/wics.1310

Andrade C. (2015). Bioequivalence of generic drugs: a simple explanation for a US Food and Drug Administration requirement. The Journal of clinical psychiatry, 76(6), e742–e744. https://doi.org/10.4088/JCP.15f10094

Fernandes, E. a. F., Van Oudtshoorn, J., Tam, A., González, L. C. A., Aurela, E. G., Potthast, H., Mettke, K., Kuribayashi, R., Shimojo, K., Kasuga, M., Morales, L., Rodríguez, Z., Jones, B., Ahn, C., Yun, E., Kim, S. H., Rodrigues, C., Tiong, T., Crane, C., . . . Alharf, A. (2024). The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities. Journal of Pharmacy & Pharmaceutical Sciences, 27, 12398. https://doi.org/10.3389/jpps.2024.12398

Abdollahizad, E., Haeri, A., Jouyban, A., Mogaddam, M. R. A., Abbasian, Z., & Dadashzadeh, S. (2025). Pharmacokinetics and Bioequivalence of Two Formulations of Apixaban Tablets: A Double-Blind, Single-Dose, Crossover Study in Healthy Subjects. Iranian Journal of Pharmaceutical Research, 24(1), e157714. https://doi.org/10.5812/ijpr-157714

Schapkaitz, E., Ter Morshuizen, B., Cree, M. M., & Jacobson, B. F. (2024). Anti-Xa Monitoring of Apixaban (ZyQuis) in Venous Thrombo-Embolism and Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 30, 10760296241249167. https://doi.org/10.1177/10760296241249167